Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January

Atossa Genetics Inc. (NASDAQ:ATOS) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 4,696,759 shares, a growth of 29.7% from the January 15th total of 3,621,023 shares. Approximately 60.2% of the company’s stock are short sold. Based on an average daily trading volume, of 2,992,317 shares, the short-interest ratio is currently 1.6 days. Based on an average daily trading volume, of 2,992,317 shares, the short-interest ratio is currently 1.6 days. Approximately 60.2% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ATOS shares. Ascendiant Capital Markets increased their price objective on Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $95.00.

Atossa Genetics Trading Up 6.6%

Shares of NASDAQ:ATOS opened at $4.20 on Monday. The stock has a market capitalization of $36.20 million, a PE ratio of -1.17 and a beta of 1.36. Atossa Genetics has a 1 year low of $3.76 and a 1 year high of $19.35. The firm has a fifty day moving average price of $9.04 and a 200 day moving average price of $11.37.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Hudson Bay Capital Management LP acquired a new stake in Atossa Genetics in the 2nd quarter worth approximately $26,000. Gallagher Capital Advisors LLC bought a new position in shares of Atossa Genetics in the third quarter valued at approximately $27,000. JPMorgan Chase & Co. lifted its stake in shares of Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after buying an additional 35,474 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in shares of Atossa Genetics during the 2nd quarter worth $49,000. Finally, Bank of America Corp DE grew its stake in Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares during the last quarter. 12.74% of the stock is owned by institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.